European Commission approves Teva inhaler; Purdue researchers develop new cancer detection method; Alnylam releases new RNAi data;

> The European Commission granted Teva Pharmaceuticals permission to market its DuoResp Spiromax multi-dose dry powder inhaler for the treatment of patients of asthma and chronic obstructive pulmonary disease. Release

> Researchers at Purdue University say they have developed a method of detecting and measuring the aggressiveness of cancer in living cells using gold nanoparticles. Article

> Alnyam released two pieces of data about the use of RNAi for the treatment of TTR-mediated amyloidosis at the International Symposium on Amyloidosis in Indianapolis. It presented the results of its Phase II open-label extension study (release) and pre-clinical data on its research in the arena. Release